NCT05377827View on ClinicalTrials.gov

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 10, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
T-Cell Non-Hodgkin LymphomaAcute Myeloid LeukemiaAngioimmunoblastic T-cell LymphomaEnteropathy-Associated T-Cell LymphomaMonomorphic Epitheliotropic Intestinal T-Cell LymphomaPeripheral T Cell LymphomaAnaplastic Large Cell LymphomaAdult T Cell LeukemiaAdult T Cell LymphomaT Cell Prolymphocytic LeukemiaExtranodal NK/T-cell LymphomaTransformed Mycosis FungoidesSezary SyndromePrimary Cutaneous Gamma-Delta T-Cell LymphomaHepatosplenic T-cell Lymphoma
Interventions
BIOLOGICAL

WU-CART-007

Provided by Miltenyi Biotec

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

Wugen, Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT05377827 - Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | Biotech Hunter | Biotech Hunter